PUBLISHER: Grand View Research | PRODUCT CODE: 1654212
PUBLISHER: Grand View Research | PRODUCT CODE: 1654212
The global veterinary pain management market size is expected to reach USD 3.82 billion in 2030 and is projected to grow at a CAGR of 6.80% from 2025 to 2030. The primary drivers of market growth include the advent of monoclonal antibodies in OA associated pain control, rising prevalence of diseases in animals such as osteoarthritis, rising pet ownership, increasing number of veterinarians, and increasing animal health expenditure. In May 2023, Zoetis's Librela mAb received the U.S. FDA approval for use in dog OA pain control. Moreover, pet insurance adoption is increasing due to a number of factors, including pet humanization, a growing pet population, greater initiatives by major companies, and rising veterinary care expenses.
Increasing number of veterinarians is expected to fuel the market growth. For instance, according to AVMA, there were a total of 127,131 vet practitioners in the U.S. veterinarians are now better equipped with tools and knowledge to identify and address pain in animals, whether it's acute or chronic. Moreover, there's a greater emphasis on educating veterinarians about recognizing and managing pain in animals. Veterinary schools are incorporating pain management into their curricula, and continuing education programs keep practicing veterinarians up-to-date on the latest techniques and medications. Overall, the increasing number of veterinarians driving the veterinary pain management market reflects a positive shift towards better care and understanding of animals' needs, aligning with the broader trend of humanizing pets and recognizing their emotional and physical well-being.
Veterinary pain management has become a crucial aspect of pet care, particularly with conditions such as cancer, where pain can be a significant symptom. With the increase in cancer cases among dogs, there's likely a corresponding increase in the demand for effective pain management solutions in veterinary practice. Approximately fifty percent of dogs over the age of ten develop cancer. Cancer in dogs occurs at a rate similar to that of humans. There are certain cancers that affect cats more frequently than dogs, like lymphoma. In order to help manage pain in dogs with cancer, veterinarians frequently combine pharmaceuticals, such as analgesics and anti-inflammatory medicines, with complementary therapies, such as acupuncture and physical therapy.
Furthermore, key mergers and acquisitions, regional expansions, product launches, etc., to increase their foothold in the market. For instance, in January 2024, Ceva acquired Scout Bio, a leading biotechnology firm specializing in advanced therapies for pets. This acquisition marks a substantial advancement for Ceva, granting access to groundbreaking treatments such as monoclonal antibodies and gene therapy aimed to tackle chronic pet diseases.